BEONE MEDICINES AUS

Latest clinical program signals indexed for BEONE MEDICINES AUS.

1. A Phase 1a/1b for Advanced, metastatic or unresec… — Phase 1

   Jun 8, 2026
   Clinical update →

2. A Phase 1a/b Study Investigating the Safety for Advanced, or metastatic solid t… — Phase 1

   Jun 8, 2026
   Clinical update →

3. BFH-NCRTPD — Phase 2

   Jun 8, 2026
   Clinical update →

4. BGB-A317-290-LTE1 — Phase 3

   Jun 8, 2026
   Clinical update →

5. BGB-43395-101 — Phase 1

   Jun 8, 2026
   Clinical update →

6. BGB-11417-203 — Phase 2

   Jun 8, 2026
   Clinical update →

7. BGB-11417-105 — Phase 2

   Jun 8, 2026
   Clinical update →

8. BGB-11417-103 — Phase 2

   Jun 8, 2026
   Clinical update →

1. 2023-503235-18-00

   BGB-11417-203

   Phase 2 · active · small_molecule

   previously untreated WM, Relapsed/Refractory Waldenström’s Macroglobulinemia

   CTIS ↗
2. 2023-506888-34-00

   BGB-43395-101

   Phase 1 · active · other

   Advanced or metastatic solid tumors including hormone receptor positive (HR+), human epidermal growth factor 2 negative (HER2-) breast cancer

   CTIS ↗
3. 2023-506948-17-00

   BGB-11417 for Previously Untreated Chronic Lymphocytic Leukemia

   Phase 3 · active · small_molecule

   Previously Untreated Chronic Lymphocytic Leukemia

   CTIS ↗
4. 2023-507751-30-00

   BGB-11417-105

   Phase 2 · active · small_molecule

   relapsed or refractory multiple myeloma

   CTIS ↗
5. 2023-508881-14-00

   BGB-11417-103

   Phase 2 · active · small_molecule

   Myeloid malignancies (acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN.

   CTIS ↗
6. 2023-508883-31-00

   BGB-A317-290-LTE1

   Phase 3 · active · small_molecule

   Solid tumors and hamatological malignancies

   CTIS ↗
7. 2023-509908-15-00

   BGB-3111-306

   Phase 3 · active · small_molecule

   Mantle Cell Lymphoma

   CTIS ↗
8. 2023-509976-40-00

   BGB-3111-304

   Phase 3 · active · small_molecule

   Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

   CTIS ↗
9. 2024-511267-28-00

   Zanubrutinib

   Phase 3 · active · small_molecule

   B-cell malignancies

   CTIS ↗
10. 2024-513970-23-00

    BGB-11417-204

    Phase 2 · active · small_molecule

    Previously Untreated Chronic Lymphocytic Leukemia

    CTIS ↗
11. 2024-514216-27-00

    BGB-3227-101

    Phase 1 · active · other

    Solid tumors

    CTIS ↗
12. 2024-514704-13-00

    BGB-53038-101

    Phase 1 · active · other

    Advanced or Metastatic Solid Tumors with KRAS Mutations or Amplifications

    CTIS ↗
13. 2024-515307-19-00

    A Phase 1a/b Study Investigating the Safety for Advanced, or metastatic solid t…

    Phase 1 · active · other

    Advanced, or metastatic solid tumors with methylthioadenosine phosphorylase (MTAP) homozygous deletion and/or lost MTAP protein expression

    CTIS ↗
14. 2024-515592-35-00

    Study of BGB-11417 in Patients with Mature B Cell Malignancies

    Phase 1 · active · other

    Mature B Cell Malignancies

    CTIS ↗
15. 2024-515593-27-00

    BGB-11417-302

    Phase 3 · active · small_molecule

    relapsed or refractory mantle cell lymphoma (R/R MCL)

    CTIS ↗
16. 2024-516234-35-00

    BGB-16673-104

    Phase 2 · active · small_molecule

    Relapsed or Refractory B-Cell Malignancies

    CTIS ↗
17. 2024-517131-52-00

    BGB-11417-303CLL-RR1

    Phase 3 · active · small_molecule

    Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    CTIS ↗
18. 2024-517322-26-00

    BG-60366-101

    Phase 1 · active · other

    EGFR-Mutant Non-Small Cell Lung Cancer

    CTIS ↗
19. 2024-518829-15-00

    BGB-11417-108

    Phase 2 · active · small_molecule

    previously untreated chronic lymphocytic leukemia (CLL)

    CTIS ↗
20. 2024-518893-15-00

    BGB-16673-302

    Phase 3 · active · small_molecule

    Chronic lymphotic leukemia and Small Lymphocytic lymphoma

    CTIS ↗
21. 2025-522860-34-00

    BGB-16673-304

    Phase 3 · active · small_molecule

    Chronic lymphocytic leukemia (CLL), Small lymphocytic lymphoma (SLL)

    CTIS ↗
22. 2025-522862-58-00

    BGB-A317-316

    Phase 3 · active · small_molecule

    Locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma

    CTIS ↗
23. 2025-523165-19-00

    A Phase 1a/1b for Advanced, metastatic or unresec…

    Phase 1 · active · other

    Advanced, metastatic or unresectable solid tumors

    CTIS ↗
24. 2025-523553-34-00

    BG-75202-101

    Phase 1 · active · other

    Advanced and Metastatic Solid tumors

    CTIS ↗
25. 2025-524136-19-00

    BGB-B2033-101

    Phase 1 · active · other

    Selected Advanced or Metastatic Solid Tumors

    CTIS ↗
26. 2025-524366-21-00

    BGB-11417-304

    Phase 3 · active · small_molecule

    treatment-naive Chronic Lymphocytic Leukemia

    CTIS ↗
27. 2025-524857-15-00

    BG-C0979-101

    Phase 1 · active · other

    Advanced Solid Tumors

    CTIS ↗
28. NCT03332017

    Zanubrutinib

    Phase 2 · completed · small_molecule

    Relapsed/Refractory Follicular Non-Hodgkin Lymphoma

    CT.gov ↗
29. NCT03336333

    Zanubrutinib

    Phase 3 · active · small_molecule

    Chronic Lymphocytic Leukemia

    CT.gov ↗
30. NCT03519230

    Pamiparib capsule

    Phase 3 · active · small_molecule

    Ovarian Cancer

    CT.gov ↗
31. NCT03736889

    Tislelizumab (BGB-A317)

    Phase 2 · active · small_molecule

    MSI-H/dMMR Solid Tumors

    CT.gov ↗
32. NCT03744468

    Surzebiclimab

    Phase 2 · completed · small_molecule

    Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in

    CT.gov ↗
33. NCT03824483

    Zanubrutinib

    Phase 2 · active · small_molecule

    Chronic Lymphocytic Leukemia (CLL)

    CT.gov ↗
34. NCT03905148

    Lifirafenib

    Phase 1 · completed · small_molecule

    Solid Tumor, Adult

    CT.gov ↗
35. NCT03957590

    Tislelizumab

    Phase 3 · completed · small_molecule

    Esophageal Squamous Cell Carcinoma (ESCC)

    CT.gov ↗
36. NCT03967977

    Tislelizumab

    Phase 3 · active · small_molecule

    Urothelial Carcinoma

    CT.gov ↗
37. NCT04002297

    zanubrutinib

    Phase 3 · active · small_molecule

    Mantle Cell Lymphoma; Non-Hodgkin Lymphoma

    CT.gov ↗
38. NCT04116437

    Zanubrutinib

    Phase 2 · completed · small_molecule

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    CT.gov ↗
39. NCT04164199

    Tislelizumab

    Phase 3 · active · small_molecule

    Advanced Malignancies

    CT.gov ↗
40. NCT04170283

    Zanubrutinib

    Phase 3 · active · small_molecule

    B-cell Malignancies

    CT.gov ↗
41. NCT04172246

    Zanubrutinib

    Phase 2 · completed · small_molecule

    Mature B-cell Malignancies

    CT.gov ↗
42. NCT04221542

    AMG 509

    Phase 1 · active · small_molecule

    Prostate Cancer

    CT.gov ↗
43. NCT04277637

    Sonrotoclax

    Phase 1 · active · small_molecule

    Mature B-Cell Malignancies

    CT.gov ↗
44. NCT04282018

    BGB-10188

    Phase 2 · completed · small_molecule

    Chronic Lymphocytic Leukemia

    CT.gov ↗
45. NCT04372433

    IO-202

    Phase 1 · completed · mab

    AML With Monocytic Differentiation

    CT.gov ↗
46. NCT04379635

    Tislelizumab

    Phase 3 · active · small_molecule

    Non Small Cell Lung Cancer

    CT.gov ↗
47. NCT04466891

    ZW25 (Zanidatamab)

    Phase 2 · completed · small_molecule

    HER2-amplified Biliary Tract Cancers

    CT.gov ↗
48. NCT04486391

    Tislelizumab

    Phase 3 · terminated · small_molecule

    Classical Hodgkin Lymphoma

    CT.gov ↗
49. NCT04521231

    Blinatumomab

    Phase 2 · active · small_molecule

    B Cell Precursor Acute Lymphoblastic Leukemia

    CT.gov ↗
50. NCT04524871

    Atezolizumab

    Phase 2 · active · small_molecule

    Advanced Liver Cancers

    CT.gov ↗
51. NCT04649385

    BGB-15025

    Phase 1 · active · small_molecule

    Advanced Solid Tumor

    CT.gov ↗
52. NCT04746924

    Tislelizumab

    Phase 3 · active · small_molecule

    Non Small Cell Lung Cancer

    CT.gov ↗
53. NCT04771130

    BGB-11417

    Phase 2 · active · small_molecule

    Acute Myeloid Leukemia

    CT.gov ↗
54. NCT04883957

    BGB-11417

    Phase 1 · active · small_molecule

    Mature B-cell Malignancies

    CT.gov ↗
55. NCT04911517

    BFH-NCRTPD

    Phase 2 · active · other

    Colorectal Neoplasms

    CT.gov ↗
56. NCT04973605

    Sonrotoclax

    Phase 2 · active · small_molecule

    Relapsed/Refractory Multiple Myeloma

    CT.gov ↗
57. NCT04974047

    Tislelizumab

    Phase 2 · completed · small_molecule

    Resectable Esophageal Squamous Cell Carcinoma

    CT.gov ↗
58. NCT05006716

    BGB-16673

    Phase 2 · active · small_molecule

    B-cell Malignancy

    CT.gov ↗
59. NCT05054348

    IO-108

    Phase 1 · completed · mab

    Solid Tumor, Adult

    CT.gov ↗
60. NCT05068440

    Zanubrutinib

    Phase 2 · completed · small_molecule

    Relapsed Diffuse Large B-cell Lymphoma

    CT.gov ↗
61. NCT05100862

    Zanubrutinib

    Phase 3 · active · small_molecule

    Relapsed/Refractory Follicular Lymphoma

    CT.gov ↗
62. NCT05116085

    Tislelizumab

    Phase 2 · completed · small_molecule

    Colorectal Cancer

    CT.gov ↗
63. NCT05152147

    Zanidatamab

    Phase 3 · active · small_molecule

    Gastric Neoplasms

    CT.gov ↗
64. NCT05294731

    BGB-16673

    Phase 2 · active · small_molecule

    B-cell Malignancy

    CT.gov ↗
65. NCT05309187

    IO-202

    Phase 1 · completed · mab

    Solid Tumor, Adult

    CT.gov ↗
66. NCT05381909

    BGB-24714

    Phase 1 · terminated · small_molecule

    Solid Tumor, Adult

    CT.gov ↗
67. NCT05479994

    BGB-11417

    Phase 2 · active · small_molecule

    Leukemia

    CT.gov ↗
68. NCT05508100

    IO-108

    Phase 1 · completed · mab

    Advanced Solid Tumor

    CT.gov ↗
69. NCT05577702

    Tislelizumab

    Phase 3 · active · small_molecule

    Non Small Cell Lung Cancer

    CT.gov ↗
70. NCT05596097

    Zanubrutinib

    Phase 2 · active · small_molecule

    Diffuse Large B-cell Lymphoma (DLBCL)

    CT.gov ↗
71. NCT05635708

    Tislelizumab

    Phase 3 · active · small_molecule

    Non Small Cell Lung Cancer

    CT.gov ↗
72. NCT05661955

    BGB-A445

    Phase 2 · active · small_molecule

    Urothelial Carcinoma

    CT.gov ↗
73. NCT05707377

    Zanubrutinib

    Phase 3 · active · small_molecule

    Primary Membranous Nephropathy

    CT.gov ↗
74. NCT05828589

    BGB-21447

    Phase 1 · active · small_molecule

    Relapsed Non-Hodgkin Lymphoma

    CT.gov ↗
75. NCT05873712

    Cyclophosphamide

    Phase 2 · active · small_molecule

    Recurrent Transformed Chronic Lymphocytic Leukemia

    CT.gov ↗
76. NCT05935098

    BGB-A3055

    Phase 1 · terminated · small_molecule

    Advanced Solid Tumor

    CT.gov ↗
77. NCT05952037

    Sonrotoclax

    Phase 2 · active · small_molecule

    Waldenstrom Macroglobulinemia

    CT.gov ↗
78. NCT05981703

    BGB-26808

    Phase 1 · active · small_molecule

    Advanced Solid Tumor

    CT.gov ↗
79. NCT06010303

    LBL-007

    Phase 2 · active · small_molecule

    Esophageal Cancer

    CT.gov ↗
80. NCT06029127

    Gimistotug

    Phase 2 · completed · small_molecule

    Non-Small Cell Lung Cancer

    CT.gov ↗
81. NCT06073821

    Sonrotoclax

    Phase 3 · active · small_molecule

    CLL

    CT.gov ↗
82. NCT06093061

    CCRT with Maintenance Tislelizumab and Metronomic Capecitabine

    Phase 2 · active · other

    Nasopharyngeal Carcinoma

    CT.gov ↗
83. NCT06120283

    BGB-43395

    Phase 1 · active · small_molecule

    Advanced Solid Tumor

    CT.gov ↗
84. NCT06233942

    BG-C9074

    Phase 1 · active · small_molecule

    Advanced Solid Tumor

    CT.gov ↗
85. NCT06257264

    BG-68501

    Phase 1 · active · small_molecule

    Breast Cancer

    CT.gov ↗
86. NCT06342713

    BGB-45035

    Phase 1 · active · small_molecule

    Healthy Participants

    CT.gov ↗
87. NCT06350318

    Zanubrutinib

    Phase 2 · active · small_molecule

    Follicular Lymphoma

    CT.gov ↗
88. NCT06422520

    BGB-C354

    Phase 1 · active · small_molecule

    Advanced Solid Tumor

    CT.gov ↗
89. NCT06427941

    BGB-B2033

    Phase 1 · active · small_molecule

    Metastatic Hepatocellular Carcinoma

    CT.gov ↗
90. NCT06487858

    BGB-R046

    Phase 1 · terminated · small_molecule

    Solid Tumor

    CT.gov ↗
91. NCT06540066

    BGB-B3227

    Phase 1 · terminated · small_molecule

    Advanced Cancer

    CT.gov ↗
92. NCT06568614

    BG-89894

    Phase 1 · terminated · small_molecule

    Advanced or Metastatic MTAP-deleted Solid Tumors

    CT.gov ↗
93. NCT06585488

    BGB-53038

    Phase 1 · active · small_molecule

    Metastatic Solid Tumors

    CT.gov ↗
94. NCT06589596

    BGB-58067

    Phase 1 · active · small_molecule

    Advanced Solid Tumor

    CT.gov ↗
95. NCT06596473

    BG-C477

    Phase 1 · active · small_molecule

    Advanced Solid Tumors

    CT.gov ↗
96. NCT06598306

    Tarlatamab

    Phase 1 · active · small_molecule

    Extensive Stage Small Cell Lung Cancer

    CT.gov ↗
97. NCT06598800

    Drug: BG-T187

    Phase 1 · active · small_molecule

    Advanced Solid Tumor

    CT.gov ↗
98. NCT06625593

    BG-C137

    Phase 1 · active · small_molecule

    Advanced Solid Tumor

    CT.gov ↗
99. NCT06634589

    BGB-16673

    Phase 2 · active · small_molecule

    B-cell Malignancy

    CT.gov ↗
100. NCT06637501

     Sonrotoclax

     Phase 3 · active · small_molecule

     Chronic Lymphocytic Leukemia

     CT.gov ↗
101. NCT06685718

     BG-60366

     Phase 1 · terminated · small_molecule

     Non-Small Cell Lung Cancer

     CT.gov ↗
102. NCT06697184

     Sonrotoclax

     Phase 3 · active · small_molecule

     Chronic Lymphocytic Leukemia

     CT.gov ↗
103. NCT06742996

     Sonrotoclax

     Phase 3 · active · small_molecule

     Mantle Cell Lymphoma

     CT.gov ↗
104. NCT06756932

     BGB-21447

     Phase 1 · active · small_molecule

     Hormone-receptor-positive Breast Cancer

     CT.gov ↗
105. NCT06803680

     BGB-B455

     Phase 1 · active · small_molecule

     Advanced Solid Tumor

     CT.gov ↗
106. NCT06839053

     Rituximab

     Phase 2 · active · mab

     Chronic Lymphocytic Leukemia

     CT.gov ↗
107. NCT06846671

     BGB-16673

     Phase 3 · active · small_molecule

     CLL

     CT.gov ↗
108. NCT06849713

     Zanubrutinib

     Phase 3 · active · small_molecule

     Chronic Lymphocytic Leukemia

     CT.gov ↗
109. NCT06906809

     BGB-16673

     Phase 1 · completed · small_molecule

     Healthy Volunteers

     CT.gov ↗
110. NCT06943872

     Sonrotoclax

     Phase 3 · active · small_molecule

     Chronic Lymphocytic Leukemia

     CT.gov ↗
111. NCT06970743

     BGB-16673

     Phase 3 · active · small_molecule

     Chronic Lymphocytic Leukemia

     CT.gov ↗
112. NCT06973187

     BGB-16673

     Phase 3 · active · small_molecule

     Chronic Lymphocytic Leukemia

     CT.gov ↗
113. NCT07005713

     BGB-16673

     Phase 1 · active · small_molecule

     Chronic Spontaneous Urticaria

     CT.gov ↗
114. NCT07043400

     Subcutaneous Tislelizumab

     Phase 3 · active · small_molecule

     Metastatic Gastric Adenocarcinoma

     CT.gov ↗
115. NCT07100938

     BGB-45035

     Phase 2 · active · small_molecule

     Rheumatoid Arthritis

     CT.gov ↗
116. NCT07134088

     Blinatumomab

     Phase 2 · active · small_molecule

     Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

     CT.gov ↗
117. NCT07141511

     BG-71332

     Phase 1 · completed · small_molecule

     Healthy Volunteers

     CT.gov ↗
118. NCT07169331

     Zanubrutinib

     Approved · active · small_molecule

     Waldenström's Macroglobulinemia

     CT.gov ↗
119. NCT07181681

     BG-C0902

     Phase 1 · active · small_molecule

     Solid Tumors

     CT.gov ↗
120. NCT07222267

     BG-75202

     Phase 1 · active · small_molecule

     Breast Cancer

     CT.gov ↗
121. NCT07226349

     BG-75098

     Phase 1 · active · small_molecule

     Advanced Solid Tumor

     CT.gov ↗
122. NCT07277231

     Sonrotoclax

     Phase 3 · active · small_molecule

     Chronic Lymphocytic Leukemia

     CT.gov ↗
123. NCT07290985

     Tislelizumab

     Phase 2 · active · small_molecule

     Gastroesophageal Adenocarcinoma

     CT.gov ↗
124. NCT07339488

     PD-1/PD-L1 inhibitors

     Phase 2 · active · small_molecule

     Borderline Resectable Carcinoma

     CT.gov ↗
125. NCT07341191

     Zanubrutinib

     Phase 2 · active · small_molecule

     Mantle Cell Lymphoma

     CT.gov ↗
126. NCT07412691

     BG-A3004

     Phase 1 · active · mab

     Skin Diseases

     CT.gov ↗
127. NCT07414836

     BG-C0979

     Phase 1 · active · small_molecule

     Advanced Solid Tumor

     CT.gov ↗
128. NCT07485049

     BGB-58067

     Phase 1 · active · small_molecule

     Glioblastoma (GBM)

     CT.gov ↗
129. NCT07492641

     BGB-43395

     Phase 3 · active · small_molecule

     HR+/HER2- Breast Cancer

     CT.gov ↗
130. NCT07507526

     Tunlametinib+PD-1 mAb

     Phase 2 · active · small_molecule

     Gastric Adenocarcinoma

     CT.gov ↗
131. NCT07554521

     Tislelizumab

     Phase 2 · active · small_molecule

     Advanced Unresectable Gastric Adenocarcinoma

     CT.gov ↗
132. NCT07590102

     BGB-58067

     Phase 1 · active · small_molecule

     Healthy Volunteers

     CT.gov ↗